Journal
BLOOD
Volume 121, Issue 3, Pages 459-467Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2012-06-435644
Keywords
-
Categories
Funding
- Dutch Cancer Society [KUN2006-3699, KUN2009-4402]
- European Union (The European Network for Cell Imaging and Tracking Expertise [ENCITE]) [Health-F5-2008-201842, Pharmachild FP7-HEALTH-2010-260353]
- Netherlands Organization for Scientific Research [NWO-Vidi-917.76.363]
- Nijmeegs Offensief Tegen Kanker (NOTK) Foundation
- Radboud University Nijmegen Medical Centre
Ask authors/readers for more resources
In human peripheral blood, 4 populations of dendritic cells (DCs) can be distinguished, plasmacytoid dendritic cells (pDCs) and CD16(+), CD1c(+), and BDCA-3(+) myeloid DCs (mDCs), each with distinct functional characteristics. DCs have the unique capacity to cross-present exogenously encountered antigens (Ags) to CD8(+) T cells. Here we studied the ability of all 4 blood DC subsets to take up, process, and present tumor Ags to T cells. Although pDCs take up less Ags than CD1c(+) and BDCA3(+) mDCs, pDCs induce potent Ag-specific CD4(+) and CD8(+) T-cell responses. We show that pDCs can preserve Ags for prolonged periods of time and on stimulation show strong induction of both MHC class I and II, which explains their efficient activation of both CD4(+) and CD8(+) T cells. Furthermore, pDCs cross-present soluble and cell-associated tumor Ags to cytotoxic T lymphocytes equally well as BDCA3(+) mDCs. These findings, and the fact that pDCs outnumber BDCA3(+) mDCs, both in peripheral blood and lymph nodes, together with their potent IFN-I production, known to activate both components of the innate and adaptive immune system, put human pDCs forward as potent activators of CD8(+) T cells in antitumor responses. Our findings may therefore have important consequences for the development of antitumor immunotherapy. (Blood. 2013;121(3):459-467)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available